Population-based mammographic screening is widely accepted as an intervention to reduce overall mortality from breast cancer, but at the cost of morbidity due to false positives and substantial overdiagnosis and overtreatment of ultra-low-risk disease, as well as personal and health-economic burdens. Recent data from a modelling study strengthen the rationale for personalized, risk-based screening approaches, now being tested in multiple clinical trials.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Pashayan, N. et al. Cost-effectiveness and benefit-to-harm ratio of risk-stratified screening for breast cancer: a life-table model. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.1901 (2018).
Klompenhouwer, E. G. et al. Re-attendance at biennial screening mammography following a repeated false positive recall. Breast Cancer Res. Treat. 145, 429–437 (2014).
Dabbous, F. M. et al. Impact of a false-positive screening mammogram on subsequent screening behavior and stage at breast cancer diagnosis. 26, 397–403 (2017).
Siu, A. L., U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 164, 279–296 (2016).
Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017).
Vachon, C. M. et al. The contributions of breast density and common genetic variation to breast cancer risk. J. Natl Cancer Inst. 107, 397–400 (2015).
Esserman, L. J. et al. Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. JAMA Oncol. 3, 1503–1510 (2017).
Esserman, L. J. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer 3, 34 (2017).
Shieh, Y. et al. Breast cancer screening in the precision medicine era: risk-based screening in a population-based trial. J. Natl Cancer Inst. 109, djw290 (2017).
Acknowledgements
We thank J. Matthews, University of California, San Francisco, for his excellent editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Related links
WISDOM: http://wisdomstudy.org
MyPeBS: http://mypebs.eu
Karma: https://karmastudy.org/
PERSPECTIVE I&I: https://www.genomecanada.ca/en/personalized-risk-assessment-prevention-and-early-detection-breast-cancer-integration-and
Rights and permissions
About this article
Cite this article
Esserman, L.J., LaCroix, A.Z. Precision risk-based screening might maximize benefit and minimize harm. Nat Rev Clin Oncol 15, 661–662 (2018). https://doi.org/10.1038/s41571-018-0093-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0093-0
